1/2 We did it! It took >4yrs, many ups & downs, dogged persistence & a huge team effort. True patient-centric advocacy at work 🥳 “Medicare has released new guidance to ensure men are well informed of tmt options” ⁦PCFA⁩ ⁦RANZCR⁩ ⁦⁦USANZ⁩

2/2 “Best practice is for men diagnosed w prostate cancer to have a consultation w both a urologist and a radiation oncologist...” Finally enshrined in Medicare. Special thx to all the pts who contributed 👏🏻 Bruce Haigh PCFA Julie McCrossin AM (She/Her) Norman Swan Cancer Voices Au #radonc

Consensus Radiation Treatment Planning Guidelines Utilizing (68)Ga-DOTATATE PET/CT for Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics- Fantastic work led by ⁦Haley K. Perlow, MD⁩ ⁦Joshua D. Palmer, MD⁩ redjournal.org/article/S0360-…

(68)Ga-DOTATATE PET/ CT should be used to assist in treatment planning for resected meningiomas! That can decrease CTV expansion and avoid a geographic miss!

Christmas reminder about Frankincense (Boswellia) Boswellia AUC 387% higher with high fat meal compared to fasting In my limited experience only works if take Boswellia with fat

MRI is recommended for urethra delineation. Contraindications are tumors < 2 mm from the urethra Urethra-sparing is recommended with focal boosting to DIL. Urethral sparing is considered for dose SBRT or salvage SBRT reirradiation . 👉sciencedirect.com/science/articl…

Nice to see the application of RadOnc expanding. Although it's been around a while it is really getting national attention these days and with Positive Patient feedback!! Excellent for Radiation Therapy and #arthritis patients. pubmed.ncbi.nlm.nih.gov/39503700/ James Yu Jason Beckta Dr.

PACE-C trial results: SBRT vs moderate hypofractionation for high-risk #ProstateCancer. Zach Klaassen talks with Alison Tree 💙 on the latest results from the PACE-C trial. With 1,208 patients randomized, early findings show similar GU toxicity & slightly higher GI side effects for

PARP inhibitors + hormonal therapy boost OS & PFS in BRCA1/2-mutant & HRR-deficient mCRPC. 🧬Olaparib, Talazoparib, & Rucaparib lead efficacy despite AEs. #ProstateCancer #Oncology #PrecisionMedicine #Cancer OncoAlert Advanced Prostate Cancer Consensus Conference Critical Reviews in Oncology Hematology (CROH) ESOncology Christian Rolfo

Radiation and Melanoma: Where Are We Now? pubmed.ncbi.nlm.nih.gov/38822928/

Read the full story here: cmrijeansforgenes.org.au/news/mystery-s…

SRS en Metástasis en Tronco! linkedin.com/posts/stereota…

More data that IR thermal ablation is inferior to surgery/radiation At 5 years, the change in mean eGFR from baseline was –10·85 mL/min SBRT, –12·25 mL/min for RFA, and –13·35 mL/min for cryoablation (p=0·75) Time to pull the plug on TA

🔴Anticoagulants Pocket Card ⤵️🔹 #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros #MedX #cardiovascular #MedTwitter #medical #medEd #cardiotwitter

📢🧬Our study on SGLT2 and papillary RCC has been published! ESMO - Eur. Oncology @OncologyAdvance ➡️SGLT2 inhibitors dramatically changed the treatment of diabetes, heart failure and chronic kidney disease ❗️SGLT2 is selectively expressed in kidney ✅Our study suggest SGLT2 may be a

Prophylactic radiation therapy to the contralateral breast in BRCA1/2 mutation carriers with early breast cancer significantly the onset of contralateral breast cancer compared to surveillance alone. ja.ma/436lWiu

I’m excited to share that our publication of the first modern American case series for the treatment of Osteoarthritis (OA) with Low Dose Radiotherapy (LDRT) is now published and available online in the red journal. The American patient population differs significantly from

Jeff Ryckman David Chen Dr. Andrew Loblaw Cristian Udovicich Krishnan Patel, MD, MHS Looks like we beat you to it Drew! 😀 PSMA-PET, MRI, DIL, SBRT, toxicity, The works! pubmed.ncbi.nlm.nih.gov/40158732/

🧬🔍: Can a single blood test screen for multiple cancers? In this must-read review from Nature Reviews Clinical Oncology, authors dive deep into the current state and future directions of MCED (Multi-Cancer Early Detection) via liquid biopsy! 🧪🩸 🎯 Key Takeaways: • MCED via

72 pts with GBM in a prospective study had integrated oncology meds + Stupp protocol, had double median survival,  OS 25.4 mths, (34.4 mths if GTR), cf to 10.6 mths without integrated oncology meds. Boswelic, Curcurmin and Polydactin. pmc.ncbi.nlm.nih.gov/articles/PMC12…